Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.

Vasmatzis G, Liu MC, Reganti S, Feathers RW, Smadbeck J, Johnson SH, Schaefer Klein JL, Harris FR, Yang L, Kosari F, Murphy SJ, Borad MJ, Thompson EA, Cheville JC, Anastasiadis PZ.

Mayo Clin Proc. 2019 Nov 1. pii: S0025-6196(19)30746-3. doi: 10.1016/j.mayocp.2019.07.019. [Epub ahead of print]

PMID:
31685261
2.

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D.

Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10.

PMID:
31290996
3.

Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.

Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A.

J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1.

4.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Sep;17(9):1893-1901. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.

5.

Close encounters of the RNAi kind: the silencing life of the adherens junctions.

Kourtidis A, Anastasiadis PZ.

Curr Opin Cell Biol. 2018 Oct;54:30-36. doi: 10.1016/j.ceb.2018.03.001. Epub 2018 Mar 26. Review.

6.

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.

DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ.

Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. Review.

PMID:
29460642
7.

Cadherin complexes recruit mRNAs and RISC to regulate epithelial cell signaling.

Kourtidis A, Necela B, Lin WH, Lu R, Feathers RW, Asmann YW, Thompson EA, Anastasiadis PZ.

J Cell Biol. 2017 Oct 2;216(10):3073-3085. doi: 10.1083/jcb.201612125. Epub 2017 Sep 6.

8.

A central role for cadherin signaling in cancer.

Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ.

Exp Cell Res. 2017 Sep 1;358(1):78-85. doi: 10.1016/j.yexcr.2017.04.006. Epub 2017 Apr 12. Review.

9.

The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.

Fiorotto R, Villani A, Kourtidis A, Scirpo R, Amenduni M, Geibel PJ, Cadamuro M, Spirli C, Anastasiadis PZ, Strazzabosco M.

Hepatology. 2016 Dec;64(6):2118-2134. doi: 10.1002/hep.28817. Epub 2016 Oct 27.

10.

Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.

Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, Kachergus JM, Feathers RW, Carr JM, Crook JE, Moreno-Aspitia A, Anastasiadis PZ, Perez EA, Thompson EA.

PLoS One. 2016 Apr 14;11(4):e0153411. doi: 10.1371/journal.pone.0153411. eCollection 2016.

11.

Bringing together cell-to-cell adhesion and miRNA biology in cancer research.

Kourtidis A, Anastasiadis PZ.

Future Oncol. 2016 May;12(10):1211-4. doi: 10.2217/fon-2016-0012. Epub 2016 Feb 29. No abstract available.

PMID:
26923006
12.

PLEKHA7 defines an apical junctional complex with cytoskeletal associations and miRNA-mediated growth implications.

Kourtidis A, Anastasiadis PZ.

Cell Cycle. 2016;15(4):498-505. doi: 10.1080/15384101.2016.1141840.

13.

Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity.

Kourtidis A, Ngok SP, Pulimeno P, Feathers RW, Carpio LR, Baker TR, Carr JM, Yan IK, Borges S, Perez EA, Storz P, Copland JA, Patel T, Thompson EA, Citi S, Anastasiadis PZ.

Nat Cell Biol. 2015 Sep;17(9):1145-57. doi: 10.1038/ncb3227. Epub 2015 Aug 24.

14.

Src family kinases differentially influence glioma growth and motility.

Lewis-Tuffin LJ, Feathers R, Hari P, Durand N, Li Z, Rodriguez FJ, Bakken K, Carlson B, Schroeder M, Sarkaria JN, Anastasiadis PZ.

Mol Oncol. 2015 Nov;9(9):1783-98. doi: 10.1016/j.molonc.2015.06.001. Epub 2015 Jun 10.

15.

Pro-Tumorigenic Phosphorylation of p120 Catenin in Renal and Breast Cancer.

Kourtidis A, Yanagisawa M, Huveldt D, Copland JA, Anastasiadis PZ.

PLoS One. 2015 Jun 11;10(6):e0129964. doi: 10.1371/journal.pone.0129964. eCollection 2015.

16.

Expression of polarity genes in human cancer.

Lin WH, Asmann YW, Anastasiadis PZ.

Cancer Inform. 2015 Mar 30;14(Suppl 3):15-28. doi: 10.4137/CIN.S18964. eCollection 2015.

17.

Establishment of epithelial polarity--GEF who's minding the GAP?

Ngok SP, Lin WH, Anastasiadis PZ.

J Cell Sci. 2014 Aug 1;127(Pt 15):3205-15. doi: 10.1242/jcs.153197. Epub 2014 Jul 2. Review.

18.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA.

Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

19.

Rho GEFs in endothelial junctions: Effector selectivity and signaling integration determine junctional response.

Ngok SP, Anastasiadis PZ.

Tissue Barriers. 2013 Dec 1;1(5):e27132. doi: 10.4161/tisb.27132. Epub 2013 Nov 15.

20.

Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Assefnia S, Dakshanamurthy S, Guidry Auvil JM, Hampel C, Anastasiadis PZ, Kallakury B, Uren A, Foley DW, Brown ML, Shapiro L, Brenner M, Haigh D, Byers SW.

Oncotarget. 2014 Mar 30;5(6):1458-74.

21.

PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity.

Espejo R, Jeng Y, Paulucci-Holthauzen A, Rengifo-Cam W, Honkus K, Anastasiadis PZ, Sastry SK.

J Cell Sci. 2014 Feb 1;127(Pt 3):497-508. doi: 10.1242/jcs.120154. Epub 2013 Nov 27.

22.

The Rho guanine nucleotide exchange factor Syx regulates the balance of dia and ROCK activities to promote polarized-cancer-cell migration.

Dachsel JC, Ngok SP, Lewis-Tuffin LJ, Kourtidis A, Geyer R, Johnston L, Feathers R, Anastasiadis PZ.

Mol Cell Biol. 2013 Dec;33(24):4909-18. doi: 10.1128/MCB.00565-13. Epub 2013 Oct 14.

23.

Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.

Borges S, Döppler H, Perez EA, Andorfer CA, Sun Z, Anastasiadis PZ, Thompson E, Geiger XJ, Storz P.

Breast Cancer Res. 2013 Aug 23;15(2):R66. doi: 10.1186/bcr3460.

24.

Protein kinase D1-mediated phosphorylations regulate vasodilator-stimulated phosphoprotein (VASP) localization and cell migration.

Döppler HR, Bastea LI, Lewis-Tuffin LJ, Anastasiadis PZ, Storz P.

J Biol Chem. 2013 Aug 23;288(34):24382-93. doi: 10.1074/jbc.M113.474676. Epub 2013 Jul 11.

25.

TEM4 is a junctional Rho GEF required for cell-cell adhesion, monolayer integrity and barrier function.

Ngok SP, Geyer R, Kourtidis A, Mitin N, Feathers R, Der C, Anastasiadis PZ.

J Cell Sci. 2013 Aug 1;126(Pt 15):3271-7. doi: 10.1242/jcs.123869. Epub 2013 May 31.

26.

p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression.

Kourtidis A, Ngok SP, Anastasiadis PZ.

Prog Mol Biol Transl Sci. 2013;116:409-32. doi: 10.1016/B978-0-12-394311-8.00018-2. Review.

27.

Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, Galanis E, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2013;8(2):e56505. doi: 10.1371/journal.pone.0056505. Epub 2013 Feb 14.

28.

Phosphorylation-mediated 14-3-3 protein binding regulates the function of the rho-specific guanine nucleotide exchange factor (RhoGEF) Syx.

Ngok SP, Geyer R, Kourtidis A, Storz P, Anastasiadis PZ.

J Biol Chem. 2013 Mar 1;288(9):6640-50. doi: 10.1074/jbc.M112.432682. Epub 2013 Jan 18.

29.

VEGF and Angiopoietin-1 exert opposing effects on cell junctions by regulating the Rho GEF Syx.

Ngok SP, Geyer R, Liu M, Kourtidis A, Agrawal S, Wu C, Seerapu HR, Lewis-Tuffin LJ, Moodie KL, Huveldt D, Marx R, Baraban JM, Storz P, Horowitz A, Anastasiadis PZ.

J Cell Biol. 2012 Dec 24;199(7):1103-15. doi: 10.1083/jcb.201207009. Epub 2012 Dec 17.

30.

E-cadherin's dark side: possible role in tumor progression.

Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ.

Biochim Biophys Acta. 2012 Aug;1826(1):23-31. doi: 10.1016/j.bbcan.2012.03.002. Epub 2012 Mar 13. Review.

31.

Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype.

Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2010 Oct 27;5(10):e13665. doi: 10.1371/journal.pone.0013665.

32.

Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA.

PLoS One. 2010 May 18;5(5):e10696. doi: 10.1371/journal.pone.0010696.

33.

The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin.

Orlichenko L, Geyer R, Yanagisawa M, Khauv D, Radisky ES, Anastasiadis PZ, Radisky DC.

J Biol Chem. 2010 Jun 18;285(25):19153-61. doi: 10.1074/jbc.M109.099382. Epub 2010 Apr 15.

34.

Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and beta-catenin.

Lee SH, Peng IF, Ng YG, Yanagisawa M, Bamji SX, Elia LP, Balsamo J, Lilien J, Anastasiadis PZ, Ullian EM, Reichardt LF.

J Cell Biol. 2008 Dec 1;183(5):893-908. doi: 10.1083/jcb.200807188.

35.

p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression.

Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis PZ.

J Cell Biol. 2008 Nov 17;183(4):737-49. doi: 10.1083/jcb.200805113.

36.

A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease.

Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, Copland JA, Anastasiadis PZ.

J Biol Chem. 2008 Jun 27;283(26):18344-54. doi: 10.1074/jbc.M801192200. Epub 2008 Apr 11.

37.

Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells.

Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA.

J Biol Chem. 2007 Aug 10;282(32):23387-401. Epub 2007 Jun 12.

38.

The role of cadherins and catenins in gliomagenesis.

Barami K, Lewis-Tuffin L, Anastasiadis PZ.

Neurosurg Focus. 2006 Oct 15;21(4):E13. Review.

PMID:
17112191
39.

p120-ctn: A nexus for contextual signaling via Rho GTPases.

Anastasiadis PZ.

Biochim Biophys Acta. 2007 Jan;1773(1):34-46. Epub 2006 Sep 1. Review.

40.

p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness.

Yanagisawa M, Anastasiadis PZ.

J Cell Biol. 2006 Sep 25;174(7):1087-96. Epub 2006 Sep 18.

41.

Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2.

Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA.

J Biol Chem. 2006 Aug 25;281(34):24575-87. Epub 2006 Jun 30.

42.

Dual regulation of Rho and Rac by p120 catenin controls adipocyte plasma membrane trafficking.

Hou JC, Shigematsu S, Crawford HC, Anastasiadis PZ, Pessin JE.

J Biol Chem. 2006 Aug 18;281(33):23307-12. Epub 2006 Jun 5.

43.

RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells.

Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA.

Mol Cell Endocrinol. 2006 Jun 7;251(1-2):17-32. Epub 2006 Mar 29.

PMID:
16574311
44.

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.

Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE.

Nat Med. 2005 May;11(5):545-50. Epub 2005 Apr 17.

PMID:
15834426
45.

Continuous association of cadherin with beta-catenin requires the non-receptor tyrosine-kinase Fer.

Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, Lilien J, Balsamo J.

J Cell Sci. 2004 Jul 1;117(Pt 15):3207-19.

46.

Vertebrate development requires ARVCF and p120 catenins and their interplay with RhoA and Rac.

Fang X, Ji H, Kim SW, Park JI, Vaught TG, Anastasiadis PZ, Ciesiolka M, McCrea PD.

J Cell Biol. 2004 Apr;165(1):87-98. Epub 2004 Apr 5.

47.

Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway.

Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP.

J Biol Chem. 2004 May 21;279(21):22118-23. Epub 2004 Mar 22.

48.

A novel interaction between kinesin and p120 modulates p120 localization and function.

Yanagisawa M, Kaverina IN, Wang A, Fujita Y, Reynolds AB, Anastasiadis PZ.

J Biol Chem. 2004 Mar 5;279(10):9512-21. Epub 2003 Dec 4.

49.

A novel role for p120 catenin in E-cadherin function.

Ireton RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, Gilbert B, van Roy F, Reynolds AB.

J Cell Biol. 2002 Nov 11;159(3):465-76. Epub 2002 Nov 11.

50.

Regulation of Rho GTPases by p120-catenin.

Anastasiadis PZ, Reynolds AB.

Curr Opin Cell Biol. 2001 Oct;13(5):604-10. Review.

PMID:
11544030

Supplemental Content

Loading ...
Support Center